|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Immunomodulator
|
AC-220(Quizartinib)
| Catalogue No. : |
C13252 |
| Product Name: |
AC-220(Quizartinib) |
| Synonym: |
AC220 |
| Chemical Name: |
N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea |
| CAS No. : |
950769-58-1 |
| Structure : |
|
| Molecular Formula: |
C29H32N6O4S |
| Molecular Weight: |
560.67 |
| Purity: |
>99% HPLC |
| Usage: |
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively. AC220 exhibits low nanomolar potency in biochemical and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily. The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
